STOCK TITAN

[Form 4] CapsoVision, Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Michele Harari, a director of CapsoVision, Inc. (CV), reported changes in her beneficial ownership related to transactions dated 09/15/2025. The filing shows a disposition of 56,156 shares of common stock and an acquisition of 2,887 Restricted Stock Units (RSUs), each RSU representing the contingent right to one share. The RSUs were granted on 09/15/2025, carry a $0 acquisition price, and are scheduled to vest on December 31, 2025. The form notes earlier reporting of 187,000 shares on a Form 3 (filed July 1, 2025) and states those amounts reflect a 1-for-3.33 reverse stock split effected July 2, 2025 in connection with the issuer's IPO. The Form 4 was signed by Attorney-in-Fact on 09/17/2025.

Positive

  • RSU grant aligns director compensation with shareholder outcomes by vesting on December 31, 2025
  • Filing includes reverse split explanation, clarifying prior reported balances

Negative

  • Director disposed of 56,156 common shares, reducing direct holdings
  • Sale price for the disposed shares is not disclosed in this Form 4

Insights

TL;DR: Director sold a material block of shares and received a modest RSU grant that vests year-end.

From a governance and disclosure perspective, the filing records a significant disposition of 56,156 common shares and the simultaneous grant of 2,887 RSUs to a director. The sale reduces the director's direct holdings while the RSUs align future compensation with shareholder value upon vesting. The reverse split disclosure clarifies prior reported balances; no price per share is stated for the sale in this filing and no other compensatory terms or acceleration provisions are disclosed. Overall, this is a routine Section 16 disclosure of insider activity with clear vesting timing for the RSUs.

TL;DR: Transaction is a standard insider reporting event with scheduled vesting, not indicating immediate governance change.

The report indicates the reporting person is a director and documents both a disposal and an equity award. The RSUs are time-based with a specified vest date of December 31, 2025, which is typical for retention-based awards. The filing properly notes the prior Form 3 balance adjusted for the issuer's 1-for-3.33 reverse split. There is no disclosure here of any related-party transaction, accelerated vesting, or change in board status. Materiality for shareholders is limited to transparency on insider holdings.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Harari Michele

(Last) (First) (Middle)
C/O CAPSOVISION, INC.
18805 COX AVENUE, SUITE 250

(Street)
SARATOGA CA 95070

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CapsoVision, Inc [ CV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 56,156 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (RSU) (2) 09/15/2025 A 2,887 (3) (3) Common Stock 2,887 $0 2,887 D
Explanation of Responses:
1. The reporting person previously reported 187,000 common stock on a Form 3 filed July 1, 2025. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split of the Issuer's common stock effected by the Issuer on July 2, 2025 in connection with its initial public offering.
2. Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
3. These RSUs are scheduled to vest on December 31, 2025
Remarks:
/s/ Kang-Huai (Johnny) Wang, Attorney-in-Fact for Michele Harari 09/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
CapsoVision, Inc.

NASDAQ:CV

CV Rankings

CV Latest News

CV Latest SEC Filings

CV Stock Data

283.40M
27.71M
40.69%
0.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SARATOGA